Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

January 7, 2021

Study Completion Date

January 21, 2022

Conditions
Relapsed/Refractory RhabdomyosarcomaNon-rhabdomyosarcoma Soft Tissue SarcomaEwing Sarcoma
Interventions
DRUG

Eribulin mesylate

Intravenous infusion

Trial Locations (41)

10032

Columbia University Medical Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

17033

Penn State Health Hershey Medical Center, Hershey

17822

Geisinger Medical Center, Danville

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Nemours / A.I. duPont Hospital for Children, Wilmington

20010

Children's National Medical Center, Washington D.C.

21287

Johns Hopkins University, Baltimore

23507

Children's Hosptial of The King's Daughters, Norfolk

30322

Children's Healthcare of Atlanta, Atlanta

32207

Nemours Children's Clinic, Jacksonville

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt Ingram Cancer Center, Nashville

39216

University of Mississippi Medical Center, Jackson

40202

Norton Children's Hospital, Louisville

43205

Nationwide Children's Hospital, Columbus

44308

Children's Hospital Medical Center of Akron, Akron

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children - Indiana University, Indianapolis

48109

CS Mott Children's Hospital, Ann Arbor

50309

Blank Children's Hospital, Des Moines

53226

Children's Hospital of Wisconsin, Milwaukee

55404

Children's Hospitals and Clinics of Minnesota, Minneapolis

55455

University of Minnesota, Minneapolis

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

64108

Children's Mercy Hospital and Clinics, Kansas City

75235

Children's Medical Center, Dallas

76104

Cook Children's Medical Center, Fort Worth

78229

Methodist Children's Hospital of South Texas, San Antonio

85016

Phoenix Children's Hospital, Phoenix

90027

Children's Hospital Los Angeles, Los Angeles

Southern California Permanente Medical Group, Los Angeles

92123

Rady Children's Hospital- San Diego, San Diego

92350

Loma Linda University Cancer Center, Loma Linda

92868

Children's Hospital of Orange County, Orange

97227

Randall Children's Hospital at Legacy Emanuel, Portland

98105

Seattle Children's, Seattle

99204

Providence Sacred Heart Medical Center and Children's Hospital, Spokane

06106

Connecticut Children's Medical Center, Hartford

07601

Hackensack University Medical Center, Hackensack

08853

Rutgers cancer Institute of NJ, New Brunswick

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT03441360 - Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | Biotech Hunter | Biotech Hunter